Optimising Type 2 Diabetes Outcomes through Dapagliflozin and Sitagliptin FDC: A Gluco-Cardio-Renal Perspective

Day 1 conference highlights include news from Moderna, BridgeBio

DRRA19 hours ago 0

FDA again rejects tabelecleucel for EBV-driven post-transplant lymphoproliferative disease

DRRA20 hours ago 0

New data, nuances in managing resistant gram-negative infections

DRRA21 hours ago 0

New Year’s resolutions 2026: Lessons from colleagues

DRRA21 hours ago 0